Parviz Gharagozloo

آخرین اخبار

Parviz Gharagozloo

Dr. Parviz Gharagozloo
PharmaTech International LLC
16 Blue Spruce Drive
Pennington, NJ 08534
Phone: (609) 818-9100; (609) 213-2058
Fax: (609) 818-9109
E-mail: parviz.gharagozloo@pharmatechinternational.com
Web Page: www.pharmatechinternational.com

Specialties:

Pharmaceutical
Biotechnology
Research and Development
Medicinal Chemistry
Organic Synthesis
Patents
Due Diligence for preclinical and clinical drug candidates

Services and Expertise:

Dr. Gharagozloo is a Medicinal Chemist with over 16 years of experience in Academia, Tech Transfer, Biotech and Pharmaceutical companies.

Medicinal chemistry, drug design and development. SAR, QSAR, and all other aspects of "Hit to Lead" optimization process at GPCRs, enzymes, and ion-channels. Traditional, parallel and combinatorial synthetic organic chemistry, computational chemistry, analytical chemistry and spectroscopy, pharmacokinetics (PK) and pharmacodynamics (PD), drug solubility, Absorption Distribution Metabolism and Excretion (ADME), formulation, US and European patent laws. Licensing evaluation and Due Diligence for preclinical and clinical drug candidates. Expert Witness.

Purdue Pharma (NJ, USA): 4 years, Group Leader in Medicinal Chemistry Napp Pharmaceuticals Research (Cambridge, UK): 2 years, Head of Medicinal Chemistry Medical Research Council Technology (MRCT, London, UK): 2 years, Head of Medicinal Chemistry National Research for Medical Research (London,
UK): 6 years, Senior Medicinal Chemist

Parviz Gharagozloo obtained his BSc honors degree in Chemistry and PhD in Medicinal Chemistry from University College London under the supervision of Professor Robin Ganellin, FRS (inventor of cimetidine). To date, he has submitted 4 development candidates and is a sole inventor on a novel formulation currently in phase 3. Authored more than 50 peer-reviewed publications, patents, posters and invited presentations.

Director of American Chemical Society ICS division and a member of Society for Chemical Industry (SCI) and Society for Medicines Research (SMR).